Advanced Search
MyIDEAS: Login to save this article or follow this journal

Cost-Effectiveness Analysis of Pneumococcal Vaccination of Adults and Elderly Persons in Belgium

Contents:

Author Info

  • Diana De Graeve

    (Faculty of Applied Economics, University of Antwerp (UFSIA), Antwerp, Belgium)

  • Geert Lombaert

    (Faculty of Applied Economics, University of Antwerp (UFSIA), Antwerp, Belgium)

  • Herman Goossens

    (University Hospital of Antwerp, University of Antwerp (UIA), Antwerp, Belgium)

Abstract

Objective: To analyse the direct medical costs and effectiveness of vaccinating adults aged between 18 and 64 years and elderly persons >=65 years of age with the 23-valent pneumococcal polysaccharide vaccine. Design and setting: This was a decision-analytic modelling study from the societal perspective in Belgium. The analysis compared `vaccination' with `no vaccination and treatment'. Methods: Calculations were based on the assumption that vaccination is as effective against all pneumococcal infections as it is against invasive pneumococcal disease. Data on the incidence of pneumococcal pneumonia and meningitis, frequency of hospitalisation, mortality rates and vaccine effectiveness were derived from the international literature. Costs were derived from analysis of historical data for cases of pneumococcal infection in Belgium. Results: Vaccinating 1000 adults between the ages of 18 and 64 years gains approximately 2 life-years in comparison with the no vaccination option. However, to realise these additional health benefits requires additional costs of 11 800 European Currency Units (ECU; 1995 values) per life-year saved. Vaccinating 1000 elderly people (>=65 years) leads to >9 life-years gained as well as a small monetary benefit of ECU1250. An extensive sensitivity analysis did not greatly affect the results for the elderly population: vaccination in this age group always remained favourable, and thus it is clearly indicated from an economic point of view. A crucial assumption for both age groups is that the effectiveness of the vaccine holds for all pneumococcal pneumonia. It is clear that the results will become less favourable if this assumption is dropped. Conclusions: Preventing pneumococcal infections by vaccination clearly benefits people's health. Reimbursement can be recommended for the elderly group; however, more accurate epidemiological data are still needed to make decisions concerning routine pneumococcal vaccination in adults

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/pdfhandler.00019053-200017060-00005.pdf
Download Restriction: Pay per view

File URL: http://pharmacoeconomics.adisonline.com/pt/re/phe/fulltext.00019053-200017060-00005.htm
Download Restriction: Pay per view

As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

Bibliographic Info

Article provided by Springer Healthcare | Adis in its journal PharmacoEconomics.

Volume (Year): 17 (2000)
Issue (Month): 6 ()
Pages: 591-601

as in new window
Handle: RePEc:wkh:phecon:v:17:y:2000:i:6:p:591-601

Contact details of provider:
Web page: http://pharmacoeconomics.adisonline.com/

Related research

Keywords: Cost effectiveness; Elderly; Pharmacoeconomics; Pneumococcal infections; Pneumococcal PS23F TT conjugate vaccine; Research and development; Vaccines;

Find related papers by JEL classification:

References

No references listed on IDEAS
You can help add them by filling out this form.

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:wkh:phecon:v:17:y:2000:i:6:p:591-601. See general information about how to correct material in RePEc.

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.